The objective of this review was to examine the latest literature regarding the effectiveness
of monoclonal antibodies as COVID-19 prophylaxis therapy for immunocompromised patient …

Aims To identify and synthesize evidence regarding how coronavirus disease 2019 (COVID-
19) interventions, including vaccines and outpatient treatments, have impacted healthcare …

Introduction The COVID-19 pandemic is a major global public health crisis. More than 2
years into the pandemic, effective therapeutic options remain limited due to rapid viral …

This study investigated the allosteric action within the receptor-binding domain (RBD) of the
SARS-CoV-2 spike protein caused by class 3 monoclonal antibody (mAb) binding. As the …

Objectives To investigate the effects of SARS-CoV-2 infection, as well as short-(within 48
hours) and long-term (within 30 days) adverse events (AEs) of SARS-CoV-2 vaccines …

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), emerged in 2019 following prior outbreaks of coronaviruses like SARS and …

We read the article in this journal by Hsu et al. with great interest regarding the effect of
molnupiravir on post-acute outcomes of patients with COVID-19 1. As we pass three years …

BACKGROUND Monoclonal antibodies (mAbs) have shown clinical benefits against
coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome …

Background & Aims: Bamlanivimab is a monoclonal antibody for the treatment of mild to
moderate cases of Coronavirus disease 2019 (COVID-19). The aim of the current meta …

The pandemics caused by HIV-1 and SARS-CoV-2 have led to advancements in treatments
and vaccines. However, HIV-1 remains incurable and new SARS-CoV-2 variants challenge …